ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Infection"

  • Abstract Number: 2122 • 2019 ACR/ARP Annual Meeting

    Outcomes and Risk Factors in Septic Arthritis with Underlying Rheumatic Conditions

    Soumyasri Kambhatla1, Estefania Gauto-Mariotti 2 and Augustine Manadan 3, 1John H. Stroger Hospital of Cook County, Chicago, 2John H Stroger Hospital of Cook County, Chicago, IL, 3Rush University Medical Center, Chicago, IL

    Background/Purpose: Septic arthritis is known to cause significant morbidity due to joint destruction and mortality if timely and adequate treatment is not given. In this study,…
  • Abstract Number: 942 • 2018 ACR/ARHP Annual Meeting

    Risk of Serious Infections in Tocilizumab Versus TNF Inhibitor Initiators in Patients with RA: A Multi-Database Cohort Study

    Ajinkya Pawar1, Rishi J. Desai2, Daniel Solomon1, Sara Gale3, Min Bao4, Khaled Sarsour3, Sebastian Schneeweiss1 and Seoyoung C. Kim1, 1Brigham and Women's Hospital, Boston, MA, 2Division of Pharmacoepidemiology and Pharmacoeconimics, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 3Genentech, South San Francisco, CA, 4Roche Innovation Center, New York, NY

    Background/Purpose: While biologics are known to be associated with risk of serious infections, data on head-to-head comparison of different biologic drugs for the risk of…
  • Abstract Number: 2453 • 2018 ACR/ARHP Annual Meeting

    Staphylococcus Aureus Carriage Rates Are High in Rheumatoid Arthritis Patients on Biologics

    Susan M. Goodman1, Bo Shopsin2, Allina A. Nocon1, Andy O. Miller3, Michael W. Henry3, Sarah E. Grond1, Elianna Kaplowitz1, Thomas P. Sculco4, Linda A. Russell3, Laura T. Donlin5, Mark P. Figgie4 and Peter K. Sculco4, 1Hospital for Special Surgery, New York, NY, 2Medicine and Microbiology, New York University School of Medicine, New York, NY, 3Medicine, Hospital for Special Surgery/Weill Cornell Medicine, New York, NY, 4Orthopaedic Surgery, Hospital for Special Surgery/Weill Cornell Medicine, New York, NY, 5Arthritis and Tissue Degeneration Program and the David Z. Rosensweig Genomics Research Center, Hospital for Special Surgery, New York, NY

    Background/Purpose: Patients with rheumatoid arthritis (RA) have a higher risk of surgical site infection  than patients with osteoarthritis (OA). Disease modifying therapy is widely used…
  • Abstract Number: 1220 • 2018 ACR/ARHP Annual Meeting

    The Impact of Gender on the Clinical Presentation, Management and Outcomes of Patients with Native Joint Septic Arthritis

    Lior Nissim1, Mary Louise Fowler2, Robert Shmerling3, Sarah Lieber4, Mohammad Naffaa5 and Ziv Paz4,5, 1Azrieli Faculty of Medicine, Bar-Ilan University, Safed, Israel, 2Boston University School of Medicine, Boston, MA, 3Rheumatology, Beth Israel Deaconess Medical Center, Boston, MA, 4Beth Israel Deaconess Medical Center, Boston, MA, 5Galilee Medical Center, Nahariya, Israel

    Background/Purpose: Approximately 20,000 cases of septic arthritis (SA) occur in the United States each year with 2-10 cases per 100,000 person-years in the general population.…
  • Abstract Number: 2502 • 2018 ACR/ARHP Annual Meeting

    Influence of the Treatment with Biologic Agents in the Viremia By the Endogenous Anelovirus Torque Teno Virus in Patients with Chronic Arthritis

    Maria Martin-Lopez1, Eliseo Albert2, Esther Rodriguez-Almaraz3, Isidoro Gonzalez-Alvaro4, Mario Fernandez-Ruiz5, Jose M. Aguado5, David Navarro2 and Jose L. Pablos6, 1Rheumatology Department, Instituto de Investigación Hospital 12 de Octubre, Madrid, Spain, 2Microbiology, Instituto de Investigación INCLIVA, Hospital Clínico, Valencia, Spain, 3Hospital Universitario 12 de Octubre, Madrid, Spain, 4Rheumatology Department, Hospital Universitario de La Princesa, IIS-IP, Madrid, Spain, 5Instituto de Investigación Hospital 12 de Octubre. Unit of Infectious Diseases, Madrid, Spain, 6Rheumatology, Rheumatology Department, Hospital Universitario 12 de Octubre, Spain, Madrid, Spain

    Background/Purpose: Torque teno virus (TTV) is an endogenous anellovirus that is highly prevalent in adult healthy subjects (up to 90%) without known pathogenicity. Increased replication…
  • Abstract Number: 1221 • 2018 ACR/ARHP Annual Meeting

    Serologic Screening for Coccidioidomycosis Among Medicare Beneficiaries with Rheumatic Diseases on Biologic Response Modifiers, Corticosteroids, and Dmards

    Shubha Kollampare1, C. Kent Kwoh1,2, Wei-Hsuan Lo-Ciganic3, Lili Zhou2,4, Erin L. Ashbeck2 and Dominick Sudano1, 1Division of Rheumatology, Department of Medicine, The University of Arizona, Tucson, AZ, 2University of Arizona Arthritis Center, Tucson, AZ, 3Department of Pharmacy, Practice and Science, College of Pharmacy, University of Arizona, TUCSON, AZ, 4College of Pharmacy, University of Arizona, Tucson, AZ

    Background/Purpose: The 2016 Infectious Disease Society of America (IDSA) guidelines recommend serologic screening for coccidioidomycosis (Cocci) prior to initiation of biologic response modifiers (BRMs). Current…
  • Abstract Number: 2614 • 2018 ACR/ARHP Annual Meeting

    The Effect of Secukinumab on the Immunogenicity of Influenza Vaccine in Patients with Psoriatic Arthritis

    Ori Elkayam1, Devy Zisman2, Ilana Kaufman3, Uri Arad4, Mark Berman5, Victoria Furer6, Yael Lahat1, Or Carmi1, Amir Haddad7, Muna Elias7, Daphna Paran1 and Michal Mandelbaum8, 1Department of rheumatology, Tel Aviv medical center and the Sackler Faculty of medicine, Tel Aviv University, Tel Aviv, Israel, 2Technion, Rheumatology Unit Carmel Medical Center, Haifa, Israel, 3Rheumatology, Tel-Aviv Sourasky Medical Center and the Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel, 4Rheumatology, Tel-Aviv Sourasky Medical Center, Sackler Faculty of Medicine, Tel-Aviv University, Tel Aviv, Israel, 5Rheumatology, Tel Aviv Sourasky Medical Center and the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel, 6Rheumatology, Tel Aviv Sourasky Medical Center and the Sackler Faculty of Medicine, Tel Aviv University, Tel-Aviv, Israel, 7Rheumatology Unit Carmel Medical Center, Haifa, Israel, 8Sheba medical center, Ramat Gan, Israel

    Background/Purpose: The humoral response to vaccination may be affected by the use of immunosuppressive drugs. The effect of secukinumab on the humoral response of vaccines…
  • Abstract Number: 1228 • 2018 ACR/ARHP Annual Meeting

    Spine Immobilization and Neurological Complications in Vertebral Osteomyelitis: Results from a Multicenter Prospective Observational Study

    Géraldine Bart1, Guillaume Coiffier2, Oriane Merot3, Emmanuel Hoppe4, Marion Couderc5, Denis Mulleman6, Gregoire Cormier7, Jean Marc Ziza8 and Benoit Le Goff1, 1Rheumatology, Nantes University Hospital, Nantes, France, 2Rheumatology, Rennes University Hospital, Rennes, France, 3rheumatology unit, Saint Nazaire Hospital, Saint Nazaire, France, 4Angers University Hospital, Angers, France, 5Rheumatology, CHU Gabriel Montpied, Clermont-Ferrand, France, 6Université François-Rabelais de Tours, CNRS 7292, Tours, France, 7Service de Rhumatologie, CHD de la Roche-Sur-Yon, La Roche-Sur-Yon, France, 8Medecine Interne-Rhumatologie, Groupe hospitalier Diaconesses-Croix-Saint-Simon, Paris, France

    Background/Purpose: In a previous work, we showed that neurological complication can occur in up to 40% of patients with vertebral osteomyelitis (VO). Bed rest and…
  • Abstract Number: 2717 • 2018 ACR/ARHP Annual Meeting

    Factors Predicting Severe Infections in Patients with Systemic Necrotizing Vasculitides Based on Data from 733 Patients Enrolled in Randomized–Controlled Trials

    Lafarge Antoine1, Christian Pagnoux2, Xavier Puéchal3, Maxime Samson4, Mohamed Hamidou5, Alexandre Karras6, Thomas Quémeneur7, Matthieu Groh8, Luc Mouthon3, Loïc Guillevin3 and Benjamin Terrier9, 1Medecine Interne, National Referral Center for Rare Systemic Autoimmune Diseases, Paris Cochin, France, Paris, France, 2Division of Rheumatology, Division of Rheumatology, Mount Sinai Hospital, Toronto, ON, Canada, 3Department of Internal Medicine, INSERM Unité 1016, Centre de Référence pour les Maladies Auto-immunes Rares, National Referral Center for Rare Systemic Autoimmune Diseases, Paris Cochin, France, Paris, France, 4Department of Internal Medicine and Clinical Immunology, François-Mitterrand Teaching Hospital, University of Bourgogne-Franche-Comté, Dijon, France, 5Department of Internal Medicine, CHU de Nantes, France, Nantes, France, 6Department of Nephrology, Hôpital Européen Georges Pompidou, APHP, Paris, France, Paris, France, 7Department of Internal Medicine, CH of Valenciennes, France, Valenciennes, France, 8Internal Medicine, Foch, Suresnes, France, 9National Referral Center for Rare Systemic Autoimmune Diseases, Paris Cochin, France, Paris, France

    Background/Purpose: Although overall survival of patients with systemic necrotizing vasculitides (SNVs) has improved markedly over the last 20 years, infectious complications remain a major cause…
  • Abstract Number: 1229 • 2018 ACR/ARHP Annual Meeting

    Diagnosing Prosthetic Joint Infections in Patients with Inflammatory Arthritis

    Serene Z. Mirza1, Shawn Richardson2, Cynthia Kahlenberg2, Jason Blevins2, Michelle Demetres3, Lily Martin3, Jackie Szymonifka2, Peter K. Sculco4, Mark P. Figgie5 and Susan M. Goodman2, 1Rheumatology, Hospital for Special Surgery, New York, NY, 2Hospital for Special Surgery, New York, NY, 3Weill Cornell Medicine, New York, NY, 4Orthopaedic Surgery, Hospital for Special Surgery/Weill Cornell Medicine, New York, NY, 5Surgery, Hospital for Special Surgery, New York, NY

    Background/Purpose: Patients with inflammatory arthritis (IA) are at increased risk of prosthetic joint infections, yet differentiating between septic and aseptic failure is a  challenge in…
  • Abstract Number: 2832 • 2018 ACR/ARHP Annual Meeting

    Multiple Subpopulations of Peripheral Lymphocytes Were Absolutely Decreased in SLE Patients with Infection and Restored By Low-Dose IL-2

    Sheng-Xiao Zhang1, Xiao-Yan Wu2, Jing Luo3, Guang-Ying Liu2, Chong Gao4, Cai-Hong Wang5 and Xiao-Feng Li5, 1The Second Hospital of Shanxi Medical University, Taiyuan, China, 2Rheumatology, The Second Hospital of Shanxi Medical University, Taiyuan, China, 3the Second Hospital of Shanxi Medical University, Taiyuan, China, 4Department of Pathology, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, Cambridge, MA, 5The Second Hospital of Shanxi Medical Univerity, Taiyuan, China

    Background/Purpose: Systemic lupus erythematosus (SLE) is a heterogeneous autoimmune disorder characterized by disturbed cellular and humoral immune responses. Dysregulations of intrinsic or adaptive immune system…
  • Abstract Number: 1231 • 2018 ACR/ARHP Annual Meeting

    Pyogenic Vertebral Osteomyelitis: Outcome Variables Analysis in a 116 Patients Cohort at a Tertiary Hospital during the Last 8 YEARS

    Jorge Juan Fragio Gil1, Roxana Gonzalez Mazario1, Francisco Miguel Ortiz-Sanjuán1, Jose Ivorra Cortes1, Elena Grau Garcia1, Karla Arevalo1, Isabel Martinez Cordellat1, Inmaculada Chalmeta Verdejo1, Jose Eloy Oller Rodriguez1, Luis Gonzalez Puig1, Marta De la Rubia Navarro1, Rosa Negueroles Albuixech1, Cristina Alcañiz Escandell2, Elvira Vicens Bernabeu1, Eva Calabuig3, Maria Tasias Pitarch3, Miguel Salavert Lleti3 and Jose Andres Roman Ivorra1, 1Rheumatology Department. Hospital Universitario y Politecnico La Fe, Valencia, Spain, 2IIS La Fe, Valencia, Spain, 3Infectious Diseases Unit. Hospital Universitario y Politecnico La Fe, Valencia, Spain

    Background/Purpose: Vertebral Osteomyelitis is an infectious disease of the vertebral body which could involve the intervertebral space (spondylodiscitis). Early diagnosis and treatment are essential in…
  • Abstract Number: 2858 • 2018 ACR/ARHP Annual Meeting

    Gaps in Patient Safety Performance before Treatment with Biologic Disease-Modifying Antirheumatic Drugs or Tofacitinib in a Large Academic Healthcare System

    Sarah L. Patterson1, Michael Evans2, Ishita Aggarwal3, Zara Izadi4, Milena Gianfrancesco5, Gabriela Schmajuk6 and Jinoos Yazdany7, 1Division of Rheumatology, University of California, San Francisco, San Francisco, CA, 2University of California - San Francisco, San Francisco, CA, 3Medicine, Santa Clara Valley Medical Center, San Jose, CA, 4Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA, 5Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA, 6San Francisco VA Medical Center, San Francisco, CA, 7University of California, San Francisco, San Francisco, CA

    Background/Purpose: Treatment with biologic disease-modifying antirheumatic drugs (DMARDs) and tofacitinib confer increased risk of life-threatening infections, including reactivation of latent tuberculosis infection (LTBI), hepatitis B…
  • Abstract Number: 218 • 2018 ACR/ARHP Annual Meeting

    Risk of Serious Infection Associated with TNF Inhibitor Versus Triple Therapy in Rheumatoid Arthritis Patients

    Yinzhu Jin1, Eun Ha Kang2, Rishi J. Desai3, Angela Tong1 and Seoyoung C. Kim4,5, 1Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 2Division of Rheumatology, Department of Internal Medicine, Seoul National University Bundang Hospital, Gyeonggi-do, Korea, Republic of (South), 3Division of Pharmacoepidemiology and Pharmacoeconimics, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 4Division of Pharmacoepidemiology and Pharmocoeconomics, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 5Rheumatology, Immunology and Allergy, Brigham and Women’s Hospital, Boston, MA

    Background/Purpose: Treatment with tumor necrosis factor inhibitor (TNFi) with methotrexate or triple therapy (MTX, sulfasalazine, and sulfasalazine) is considered in patients with rheumatoid arthritis (RA)…
  • Abstract Number: 1233 • 2018 ACR/ARHP Annual Meeting

    Rituximab Safety in Patients with Rheumatoid Arthritis. an Eleven-Year Follow-up Observational Study

    Raul Castellanos-Moreira Sr.1, Sebastian C Rodriguez-Garcia1, M. Victoria Hernández2, Virginia Ruiz-Esquide3, Oscar Camacho Sr.1, Andrea Cuervo1, Julio Ramírez3, Juan Cañete1, Jose Gomez Puerta1 and Raimon Sanmarti1, 1Rheumatology Service, Hospital Clínic de Barcelona, Barcelona, Spain, 2Rheumatology, Hospital Clinic. Barcelona. Spain, Barcelona, Spain, 3Rheumatology, Hospital Clínic de Barcelona, Barcelona, Spain

    Background/Purpose:  Rituximab (RTX) is a chimeric monoclonal antibody approved for the treatment rheumatoid arthritis (RA) patients who failed to respond to tumor necrosis factor inhibitors.…
  • « Previous Page
  • 1
  • …
  • 20
  • 21
  • 22
  • 23
  • 24
  • …
  • 32
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology